Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6

Reymen, D.; Naesens, Lieve; Balzarini, Jan; Holý, Antonı́n; Dvořáková, Hana; Clercq, Erik De

doi:10.1016/0166-3542(95)00058-5

Cited by 93 publications

(62 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inconsistencies in these reports could be due to the differential susceptibilities to ganciclovir between variants HHV-6A and HHV-6B. Studies have demonstrated that HHV-6B is less susceptible to ganciclovir when compared to HHV-6A [76,77] . In the clinical setting, this differential susceptibility could partly explain the occurrence of HHV-6B (but not HHV-6A) infections in a large cohort of solid organ transplant recipients who received anti-CMV prophylaxis with ganciclovir or valganciclovir [41] .…”

Section: Mechanism Of Antiviral Resistancementioning

confidence: 84%

“…Cidofovir is an acyclic nucleoside phosphonate analogue that has been shown to have excellent activity against HHV-6 in vitro [76] . There have been clinical reports where cidofovir was used successfully to treat HHV-6 infections.…”

Section: Cidofovirmentioning

confidence: 99%

“…Acyclovir [73,81] No No Ganciclovir [66][67][68][70][71][72] Yes Yes Mutation in U38 DNA polymerase Mutation in U69 phosphotransferase Foscarnet [65,[82][83][84][85] Yes Yes 2 Mutation in U38 DNA polymerase Cidofovir [76,86,95] Yes Yes Mutation in U38 DNA polymerase Maribavir [87,88] No Not available Cyclopropavir [89] Yes…”

Section: Mechanism Of Antiviral Resistancementioning

confidence: 99%

See 2 more Smart Citations

Human herpesvirus 6 infections after liver transplantation

Massih¹,

Razonable²

2009

WJG

View full text Add to dashboard Cite

show abstract

Section: Mechanism Of Antiviral Resistancementioning

confidence: 84%

Section: Cidofovirmentioning

confidence: 99%

Section: Mechanism Of Antiviral Resistancementioning

confidence: 99%

See 1 more Smart Citation

Human herpesvirus 6 infections after liver transplantation

Massih¹,

Razonable²

2009

WJG

View full text Add to dashboard Cite

show abstract

“…50 Foscarnet on the other hand appears to be active against HHV6 both in vitro and in vivo, 51,52 but can cause severe nephrotoxicity when administered at therapeutic levels. 53 Cidofovir showed excellent anti HHV6 activity in vitro, 54 and seems to be the most effective Methylenecyclopropane analog Good activity 7.8 Preclinical phase a EC50: 50% antiviral effective concentration. All EC50 concentrations are determined in MOLT-3 T-cell lines, infected with laboratory strain HHV6-B, variant Z-29.…”

Section: Prevention and Therapy Of Hhv6 Reactivationmentioning

confidence: 99%

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Pagter

Schuurman

Meijer

et al. 2008

Journal of Clinical Virology

View full text Add to dashboard Cite

a b s t r a c tHuman herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in increased morbidity and mortality after HSCT remains unclear. This review will focus on the current available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular emphasis on the severe complication GvHD. At present, no effective specific antiviral treatment for HHV6 reactivation has been identified. The currently available antiviral agents are outlined, as well as possible future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure.

show abstract

“…Valaciclovir and famciclovir have a similar antiviral spectrum of action. [3][4][5][6][7][8][9][10] Valaciclovir inhibits reactivation of CMV in organ transplant patients. 3 Famciclovir was continued rather than valaciclovir because valaciclovir is excreted by the kidney and has potential renal toxicity.…”

Section: Case Reportmentioning

confidence: 99%

Beneficial response of cervical dystonia spasmodic torticollis to cidofovir, an acyclic phosphonate analog (s-1-3-hydroxy-2- phosphonylmethoxypropyl) of cytosine

Lerner¹,

Beqaj²

2014

VAAT

View full text Add to dashboard Cite

Abstract:We report the case of a 23-year-old healthy man who had sudden onset of cervical dystonia spasmodic torticollis in October 2012. He was treated with intravenous cidofovir, which was started on February 20, 2013, followed by oral valganciclovir and famciclovir. Pulling of the neck and tilt of the head far to the left is no longer present (as at April 22, 2014). Human herpesvirus 6 total antibody titers fell from 11.27 (negative ,1) on January 15, 2013 to 1.89 on August 5, 2013. To our knowledge, this is the first case of improvement in cervical dystonia spasmodic torticollis with treatment.

show abstract

Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6

Cited by 93 publications

References 42 publications

Human herpesvirus 6 infections after liver transplantation

Human herpesvirus 6 infections after liver transplantation

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Beneficial response of cervical dystonia spasmodic torticollis to cidofovir, an acyclic phosphonate analog (s-1-3-hydroxy-2- phosphonylmethoxypropyl) of cytosine

Contact Info

Product

Resources

About